Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
16 April 2020 | Story Department of Communication and Marketing | Photo Charl Devenish
Farmovs
In 2019, FARMOVS was pre-qualified by the WHO to support clinical studies aimed at improving access to quality generic medicines across the globe.

The University of the Free State (UFS) is committed to supporting government’s efforts to overcome the COVID-19 pandemic. During this challenging time, dedicated staff members at the UFS continue to provide services as a testimony to their commitment to advance public knowledge of COVID-19 for the greater good of South Africa.

The following is a synopsis of the areas in which the UFS is actively assisting.

Public Health Emergency Solidarity Trial
Clinicians from the Department of Internal Medicine, the Department of Critical Care, and the Division of Virology will be working with FARMOVS to participate in the Public Health Emergency Solidarity Trial initiated by the World Health Organization (WHO). This international randomised trial will evaluate four treatment options (remdesivir, lopinavir/ritonavir, lopinavir/ritonavir plus interferon, chloroquine or hydroxychloroquine) for the treatment of COVID-19. 

The trial is expected to include more than 45 countries worldwide, including a number of South African sites. 

Farmovs

FARMOVS is in a planning process to support all the Bloemfontein hospitals, including Pelonomi, Universitas, 3 Military Hospital, Mediclinic, and Rosepark, in conducting the largest global trial on COVID-19 – the Public Health Emergency Solidarity Trial, under leadership of the WHO.   

Negotiations are ongoing between the UFS and the Department of Health in the Free State for FARMOVS to offer support with the continuation of healthcare to non-COVID-19 patients in an attempt to free up space at Universitas Hospital for isolation of COVID-19 patients. 

In 2019, FARMOVS was pre-qualified by the WHO to support clinical studies aimed at improving access to quality generic medicines across the globe.  FARMOVS also receives feasibility requests for support with the evaluation of existing drugs (repurposing) as well as the development of novel drugs for the treatment of COVID-19 – this is an ongoing process.

Disaster Management Training and Education Centre (DiMTEC)
DiMTEC represents the UFS on the Provincial Joint Operation Centre (PROVJOC). The PROVJOC is a fully equipped, dedicated facility that is proactively established to enable all relevant role players /disciplines to jointly manage all safety and security-related aspects of any planned event or any major incident which has occurred or is imminent – especially in the response and recovery operations phase – at the strategic and/or tactical level, using the Unified Command System. This facility is also linked to all other established safety and security centres.

Research and Innovation
The UFS hosts a SARChI Research Chair in vector-borne and zoonotic diseases, and recently invested in the establishment of a biosafety level-3 facility. Hence, there is expertise on the campus to plan and conduct research on zoonotic and medically significant viruses. In addition, there are research groups focusing on protein expression systems with potential for utilisation in the development of diagnostic assays with application in either diagnosis or surveillance.

Currently, researchers at the UFS have established several projects that will contribute directly towards the COVID-19 outbreak.


News Archive

UFS waives application fees for studies in 2016
2015-10-22

The University of the Free State (UFS) has waived application fees for all prospective undergraduate and postgraduate students - nationally and internationally - who want to study at the institution in 2016.

"Universities charge application fees that vary in amount. With 25 universities in South Africa, this fee becomes a burden for students who want to apply to more than one university. The university leadership has also realised that tens of thousands of students who qualify for university entrance stumble at the first hurdle: finding the money to apply,” says Prof Jonathan Jansen, Vice-Chancellor and Rector.

According to Prof Jansen, the UFS would like to set an example and a challenge to all public universities to scrap the application fee, so that many more young people from poor communities can realise their dream of accessing higher education. At the same time, the universities will benefit from more top talent coming into higher learning. "The more students that enrol and graduate, the stronger the financial position of universities will be; it is a win-win policy, and the university leadership has done the maths on this," he says.
 
The application fees for 2016 were R235 for South African students and R500 for international students. Prospective students, who have already applied for admission in 2016, will not be refunded. However, students who have already registered successfully for 2016 may apply to have the application fee credited to their tuition fee account after they have registered next year.
 
To support this initiative, UFS Marketing will be conducting an on-site application campaign by visiting East London, Port Elizabeth, Kimberley, Qwaqwa, Kathu, Pretoria, Johannesburg, Newcastle, Durban, Pietermaritzburg, and Ladysmith from 28 August 2015. Further details of the venues in each town will be available on the Kovsie2b Facebook page.

All prospective students currently doing their final-year undergraduate studies at either the UFS or any other university will also pay no registration fee if they want to continue with an Honours degree in 2016. The registration fee for 2016 was R950.
 
The closing date for applications for admission is 31 December 2015.

Apply for undergraduate or postgraduate studies at the UFS for 2016.

For enquiries, please call +27(0)51 401 9111.

 

 

 

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept